Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

September 30, 2017

Primary Completion Date

January 31, 2018

Study Completion Date

March 31, 2018

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

Tilmanocept

Intravenously administered Technetium Tc 99m tilmanocept